Emerging role of genipin as a therapeutic in diseases of the peripheral nervous system

Genipin is bioactive compound derived from the fruit of Gardenia jasminoides that has been implicated in three primary contexts. First, as the active component of Traditional Chinese Medicine, genipin has been used for centuries to treat various inflammatory conditions. Second, genipin is widely employed in bioengineering as a low-cytotoxicity crosslinking agent to stabilize and stiffen extracellular matrices and biomaterials. Third, purified genipin has been reported to confer therapeutic benefits across a broad spectrum of disease models, including metabolic, inflammatory, and neurodegenerative conditions. The breadth of these applications raises a possible mechanistic question: does genipin exert multiple independent molecular effects, or do its diverse biological outcomes arise from a single upstream mechanism? We propose that genipin’s extracellular matrix (ECM) crosslinking activity may represent an important and underexplored upstream mechanism of action. Specifically, we hypothesize that ECM crosslinking alters the biophysical microenvironment in a manner that subsequently modulates mitochondrial function and inflammatory signaling pathways, ultimately leading to the reported therapeutic effects. We further posit that this mechanism is particularly relevant within the peripheral nervous system. In both human cell-based and murine models, genipin protects against neurodegeneration and enhances regeneration following axonal injury. Chemical abrogation of genipin’s crosslinking capability removes these effects, supporting a causal relationship between matrix crosslinking and neuroprotection. Collectively, these observations suggest that inhibition of genipin’s crosslinking activity abrogates its therapeutic efficacy. We therefore propose that genipin’s ECM crosslinking capacity may constitute an upstream biological function, explaining its wide-ranging applications and positioning it as a promising biologically derived therapeutic agent.